RetinalGenix Technologies (RTGN) Common Equity (2020 - 2026)

RetinalGenix Technologies has disclosed Common Equity across 7 years of filings, most recently posting -$2.6 million for Q1 2026.

• Common Equity for Q1 2026 came in at -$2.6 million, down 53.37% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.6 million (down 53.37% YoY), and the FY2025 annual result was -$2.3 million, down 57.43% from the prior year.
• Common Equity came in at -$2.6 million for Q1 2026 at RetinalGenix Technologies, down from -$2.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of -$675175.0 in Q2 2022 to a low of -$2.6 million in Q1 2026.
• The 5-year median for Common Equity is -$1.5 million (2024), against an average of -$1.6 million.
• Across the five-year window, Common Equity sank 1789.02% in 2022 and fell 1.17% in 2024, its largest moves.
• RetinalGenix Technologies' Common Equity stood at -$1.1 million in 2022, then tumbled by 31.48% to -$1.4 million in 2023, then slipped by 4.05% to -$1.5 million in 2024, then slumped by 57.43% to -$2.3 million in 2025, then slipped by 11.09% to -$2.6 million in 2026.
• The last three Common Equity figures came in at -$2.6 million (Q1 2026), -$2.3 million (Q4 2025), and -$2.2 million (Q3 2025), per Business Quant data.